Advanced Search Close Search
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Tradeshow News

Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

  • By Alzamend Neuro, Inc.

Neuroscience 2026, the annual meeting of the Society for Neuroscience, will be held November 14–18, 2026 in Washington, DCPresentation Title: Assessing Treatment-Associated Brain Network Changes Following a Novel Lithium Treatment Using 7T Resting-State fMRI – Results from a Randomized Phase 1/2A Clinical Trial

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Clinical Trials Medical Discoveries

Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

  • By Alzamend Neuro, Inc.

ISMRM Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR will be held September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, SpainPresentation will report first-of-its-kind pharmacokinetic imaging results from Phase 1/2A trial of AL001, Alzamend's novel organic lithium drug candidate, in healthy human subjects